Overview

A class action lawsuit has been filed against Agenus, Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) and certain of the Company’s current and former senior executive officers alleging violations of the federal securities laws.  The Agenus class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, both dates inclusive (the “Class Period”).  Investors have until November 5, 2024, to seek appointment as lead plaintiff of the Agenus class action lawsuit.

Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the United States and internationally.  Among other product candidates, the Company is developing balstilimab, an anti-PD-1 antagonist that has completed a Phase 2 clinical trial to treat second line cervical cancer; and botensilimab (AGEN1181), an antigen 4 (CTLA-4) blocking antibody that is in a Phase 2 clinical trial for the treatment of pancreatic cancer and melanoma.  Agenus purports to pursue clinical trials “designed to strengthen the efficacy and safety signals demonstrated to date and that may support a potential filing for full approval and/or accelerated approval based on the magnitude of benefit demonstrated” and, according to the Company, its strategy “revolves around pioneering optimal combination treatments for cancer patients, with botensilimab as [its] cornerstone.”  In particular, Agenus has focused on the development of the “botensilimab/balstilimab combination,” the Company’s investigational therapy for the treatment of patients with metastatic colorectal cancer (“CRC”).

The Agenus class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; (2) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as a lead plaintiff in the Agenus class action lawsuit is November 5, 2024.